Wall Street brokerages predict that Merus NV (NASDAQ:MRUS) will report $2.72 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Merus’ earnings, with the highest sales estimate coming in at $3.40 million and the lowest estimate coming in at $2.05 million. Merus reported sales of $1.20 million during the same quarter last year, which indicates a positive year-over-year growth rate of 126.7%. The company is scheduled to report its next earnings results on Friday, April 27th.
On average, analysts expect that Merus will report full-year sales of $2.72 million for the current fiscal year, with estimates ranging from $13.59 million to $14.35 million. For the next financial year, analysts expect that the company will report sales of $17.28 million per share, with estimates ranging from $8.19 million to $26.37 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Merus.
Merus (NASDAQ:MRUS) last announced its earnings results on Thursday, November 30th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.26). Merus had a negative return on equity of 119.36% and a negative net margin of 809.20%. The company had revenue of $4.08 million during the quarter, compared to analysts’ expectations of $2.54 million.
MRUS has been the subject of several analyst reports. Jefferies Group restated a “buy” rating and set a $30.00 price target on shares of Merus in a research report on Thursday, October 26th. Zacks Investment Research upgraded shares of Merus from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. Wedbush restated an “outperform” rating and set a $32.00 price target on shares of Merus in a research report on Friday, January 12th. Royal Bank of Canada lowered shares of Merus from an “outperform” rating to a “sector perform” rating and set a $28.00 price target for the company. in a research report on Tuesday, January 2nd. Finally, BidaskClub upgraded shares of Merus from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 30th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. Merus presently has an average rating of “Hold” and an average price target of $30.25.
A hedge fund recently bought a new stake in Merus stock. Bain Capital Public Equity Management LLC purchased a new stake in shares of Merus NV (NASDAQ:MRUS) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 196,090 shares of the biotechnology company’s stock, valued at approximately $8,297,000. Bain Capital Public Equity Management LLC owned 1.01% of Merus as of its most recent SEC filing. 29.69% of the stock is owned by hedge funds and other institutional investors.
Merus (NASDAQ MRUS) traded up $0.19 during midday trading on Friday, reaching $18.01. 121,130 shares of the company’s stock traded hands, compared to its average volume of 32,139. Merus has a twelve month low of $13.23 and a twelve month high of $33.63. The stock has a market capitalization of $349.14 and a price-to-earnings ratio of -2.56.
ILLEGAL ACTIVITY WARNING: “$2.72 Million in Sales Expected for Merus NV (MRUS) This Quarter” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/20/2-72-million-in-sales-expected-for-merus-nv-mrus-this-quarter.html.
Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.
Get a free copy of the Zacks research report on Merus (MRUS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.